May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Subretinal Artificial Silicon Retina Microchip Implantation in Retinitis Pigmentosa Patients: Long Term Follow-Up
Author Affiliations & Notes
  • A.Y. Chow
    Optobionics, Wheaton, IL, United States
  • K.H. Packo
    Ophthalmology, Rush Medical Center, Chicago, IL, United States
  • J.S. Pollack
    Ophthalmology, Rush Medical Center, Chicago, IL, United States
  • R.A. Schuchard
    Ophthalmology, Atlanta VA Rehab R&D, Emory University Eye Center, Atlanta, GA, United States
  • Footnotes
    Commercial Relationships  A.Y. Chow, Optobionics E, P; K.H. Packo, None; J.S. Pollack, None; R.A. Schuchard, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4205. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.Y. Chow, K.H. Packo, J.S. Pollack, R.A. Schuchard; Subretinal Artificial Silicon Retina Microchip Implantation in Retinitis Pigmentosa Patients: Long Term Follow-Up . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4205.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the short and long-term safety and efficacy of a subretinal Artificial Silicon Retina (ASR) microchip in treating vision loss from retinitis pigmentosa Methods: A light-powered ASR microchip, 2-mm in diameter and producing electrical stimulation, was implanted into the subretinal space of 10 patients with retinitis pigmentosa. Pre- and postoperative objective and subjective assessment of visual function were performed and included testing of ETDRS letters, color perception, automated visual fields, ERGs and custom tests for motion detection and visual angle resolution. Postoperative visual function testing was conducted for greater than 2 1/2 years along with clinical and laboratory evaluation of chip function and safety. Results: ASR chips were readily implanted into the subretinal space of 10 patients and appear to be safely tolerated for at least 2 1/2 years in some patients with persistence of implant electrical activitiy. Visual function improvement, first noted at 2 to 6 weeks after surgery, was still present 2 1/2 years post implantation in the longest implant group and involved visual field areas distant from the implant. Conclusions: In this pilot study, subretinal ASR chips seem to be well tolerated in retinitis pigmentosa patients and appear to produce improved and persistent visual funciton possibly related to a neurotrophic effect.

Keywords: retinitis • retina • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×